A product portfolio of innovative molecular imaging probes, that address major clinical needs in oncology (inter alia prostate cancer), neurodegenerative and cardiovascular diseases, is a testimony to our intensive research and development.
Our lead compound is [18F] florbetaben – an 18F-labeled tracer used in Positron Emission Tomography (PET). Florbetaben specifically binds to beta-amyloid deposits in the brain, a key pathological hallmark in Alzheimer's Disease. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have recently approved Neuraceq™ (Florbetaben F18 injection) for PET Imaging of Beta-Amyloid Neuritic Plaques in the brain.Visit Website
Pharma Solutions is one of the largest manufacturing companies in the world that provides tractability and scalability of operations.Read More
Creating value for patients and care providers through innovative solutions is Critical Care’s sole area of focus.Read More
The healthcare vertical has a Consumer Product Division, and is one of the fastest emerging players in the Domestic Consumer Healthcare market.Read More
PhytoMedicine™ develops and markets standardised healthcare solutions derived from natural sources such as plants.Read More